Physician profile
Susan D Wolf
NPI 1043206261
$14,659.48
in general payments reported to CMS, 2019-2025
33 companies · $1,979 in 2025
The $1,979 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,009 · 2020: $770 · 2021: $1,624 · 2022: $2,186 · 2023: $2,669 · 2024: $2,423 · 2025: $1,979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,891 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,891.39 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,262.00 | 2019-2025 | Skyrizi, Rinvoq |
| Leo Pharma INC. | $1,384.86 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $1,382.55 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $1,329.55 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Pfizer INC. | $1,326.98 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,003.54 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $877.55 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Angiodynamics, INC. | $660.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $637.05 | 2019-2025 | |
| Genzyme Corporation | $611.68 | 2019-2025 | |
| Ucb, INC. | $609.16 | 2020-2025 | Bimzelx |
| Incyte Corporation | $513.21 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $351.81 | 2019-2024 | Siliq, Arazlo, Jublia |
| Dermavant Sciences, INC. | $281.87 | 2023-2024 | Vtama |
| Amgen INC. | $260.93 | 2020-2025 | Otezla, Otezla |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $235.94 | 2021-2025 | Nemluvio |
| Allergan, INC. | $149.84 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $138.90 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $99.77 | 2019 | |
| Arcutis Biotherapeutics, INC. | $89.46 | 2024-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.93 | 2024 | Spevigo |
| Vyne Pharmaceuticals INC. | $71.70 | 2020-2021 | |
| Epi Health, LLC | $44.52 | 2019 | |
| Journey Medical Corporation | $36.21 | 2022-2023 | |
| Merz North America, INC. | $33.26 | 2025 | |
| Organogenesis INC. | $32.66 | 2021 | |
| Organon LLC | $30.95 | 2025 | Vtama |
| Biofrontera INC. | $25.79 | 2025 | |
| Dermira, INC. | $24.63 | 2021 | |
| Mylan Pharmaceuticals INC. | $24.40 | 2019 | |
| Almirall LLC | $22.05 | 2019 | |
| Mission Pharmacal Company | $14.69 | 2019 | |
| Dusa Pharmaceuticals, INC. | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.